Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of IPI-926 in Patients With Metastatic or Locally Advanced (Unresectable) Chondrosarcoma

NCT01310816 is registered in ClinicalTrials.gov with Infinity Pharmaceuticals, Inc. as lead sponsor.

NCT NCT01310816
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01310816 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of IPI-926 in Patients With Metastatic or Locally Advanced (Unresectable) Chondrosarcoma
Lead sponsor
Infinity Pharmaceuticals, Inc.
Phase
Phase 2
Overall status
Completed
Start date
February 28, 2011
Completion date
December 31, 2013
Enrollment
105 (actual)
Sites
36

Conditions

As the registry lists them; a condition with its own page is linked.

conventional chondrosarcoma